

11 June 2025

Completion of Share Consolidation

EVE Health Group (ASX:EVE, EVE or the Company), today announces that the consolidation of the issued capital of the Company on a forty (40) to one (1) basis, as approved by shareholders at the General Meeting of the Company held on 29 May 2025 is now complete.

The Company's post-consolidation capital structure is as follows:

Class	Number
Ordinary Shares	131,862,715

New holding statements are being dispatched to security holders advising them of their security holding on a post-consolidation basis. Where the consolidation has resulted in a fraction of a security held, that fractional entitlement has been rounded up to the nearest whole security.

Trading on a normal T+2 settlement basis will commence on 12 June 2025.

Authorised for release by Bill Fry, Managing Director.

— ENDS —

For more information, please contact:

Company enquiries

Bill Fry, Managing Director & CEO
EVE Health Group Ltd
+61 8 6465 5500
billf@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract, which is being acquired, EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.